Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2013 2
2014 2
2015 1
2017 1
2018 2
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Leon's helmet.
Gonzalez H, Marceau-Renaut A, Spentchian M, Hassoun M, Guignedoux G. Gonzalez H, et al. Among authors: spentchian m. Haematologica. 2023 May 1;108(5):1450-1451. doi: 10.3324/haematol.2022.281125. Haematologica. 2023. PMID: 36226490 Free PMC article. No abstract available.
Reply to J. Richter et al.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX. Rousselot P, et al. Among authors: spentchian m. J Clin Oncol. 2014 Sep 1;32(25):2823-5. doi: 10.1200/JCO.2014.56.3858. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071119 No abstract available.
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.
Kohn M, Delord M, Chbat M, Guemriche A, Merabet F, Roupie AL, Lombion N, Farhat H, Longval T, Cabannes-Hamy A, Lambert J, Marque-Juillet S, Raggueneau V, Osman J, Spentchian M, Rigaudeau S, Rousselot P, Besson C. Kohn M, et al. Among authors: spentchian m. Haematologica. 2022 Jun 1;107(6):1454-1459. doi: 10.3324/haematol.2021.280026. Haematologica. 2022. PMID: 34788987 Free PMC article. No abstract available.
Nivolumab to control molecular response in chronic myeloid leukemia.
Rousselot P, Renard P, de Buyer A, Finet A, Spentchian M, Saiag P. Rousselot P, et al. Among authors: spentchian m. Leuk Res. 2018 Sep;72:5-6. doi: 10.1016/j.leukres.2018.07.011. Epub 2018 Jul 26. Leuk Res. 2018. PMID: 30056299 No abstract available.
Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
Ruggiu M, Oberkampf F, Ghez D, Cony-Makhoul P, Beckeriche F, Cano I, Taksin AL, Benbrahim O, Ghez S, Farhat H, Rigaudeau S, de Gunzburg N, Lara D, Terre C, Raggueneau V, Garcia I, Spentchian M, De Botton S, Rousselot P. Ruggiu M, et al. Among authors: spentchian m. Leuk Lymphoma. 2018 Jul;59(7):1659-1665. doi: 10.1080/10428194.2017.1397666. Epub 2017 Nov 28. Leuk Lymphoma. 2018. PMID: 29179634
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, Beressi JP, Verhoeyen E, Raggueneau V, Maneglier B, Castaigne S, Chomienne C, Chrétien S, Rousselot P, Leboulch P. Prost S, et al. Among authors: spentchian m. Nature. 2015 Sep 17;525(7569):380-3. doi: 10.1038/nature15248. Epub 2015 Sep 2. Nature. 2015. PMID: 26331539
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Ghez D, Micol JB, Pasquier F, Auger N, Saada V, Spentchian M, Ianotto JC, Bourhis JH, Bennaceur-Griscelli A, Terré C, Castaigne S, Rigaudeau S, Rousselot P, de Botton S. Ghez D, et al. Among authors: spentchian m. Eur J Cancer. 2013 Nov;49(17):3666-70. doi: 10.1016/j.ejca.2013.07.147. Epub 2013 Aug 19. Eur J Cancer. 2013. PMID: 23968731
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX. Rousselot P, et al. Among authors: spentchian m. J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323036
11 results